These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 7559259

  • 1. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
    Dick FR, Burns CP, Weiner GJ, Heckman KD.
    Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX.
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO.
    Cancer; 2009 Jul 01; 115(13):2922-9. PubMed ID: 19452542
    [Abstract] [Full Text] [Related]

  • 11. [Prognostic value of early treatment response in children with acute myeloid leukemia].
    Tie LJ, Gu LJ, Song DL, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Chen J, Wang YP, Zou JY.
    Zhonghua Yi Xue Za Zhi; 2006 Jul 11; 86(26):1837-40. PubMed ID: 17054861
    [Abstract] [Full Text] [Related]

  • 12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 11; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
    Kuriyama K.
    Rinsho Ketsueki; 1994 Mar 11; 35(3):267-71. PubMed ID: 8158847
    [Abstract] [Full Text] [Related]

  • 15. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    MRD-AML-BFM Study GroupDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. langebrake.claudia@mh-hannover.de, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D.
    J Clin Oncol; 2006 Aug 01; 24(22):3686-92. PubMed ID: 16877738
    [Abstract] [Full Text] [Related]

  • 16. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 01; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul 01; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 18. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 19. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
    Lemez P, Gáliková J, Haas T.
    Neoplasma; 2000 Dec 15; 47(1):41-7. PubMed ID: 10870686
    [Abstract] [Full Text] [Related]

  • 20. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H.
    Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.